Hydroxyapetite Nanoparticles, Tricalcium Phosphate Nanoparticles, and PRF for Treatment of Gingival Recession

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-09-01

Study Completion Date

2023-04-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the present study was to compare between nanocrystalline hydroxyapatite and tricalcium phosphate carried on PRP membrane in treatment of Miller's class 1 gingival recession in human.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hydroxyapetite Nanoparticles and Tricalcium Phosphate Nanoparticles Loaded on Platelet Rich Fibrin Membranes for Treatment of Gingival Recession

NCT07088809

Periodontal Diseases Gingival Recession Localized Moderate Nano-hydroxyapatite +2 more

ENROLLING_BY_INVITATION NA

Comparing Microneedling and Injectable Platelet Rich Fibrin to Hyaluronic Acid In Papilla Reconstruction

NCT07280507

Papilla Reconstruction

ACTIVE_NOT_RECRUITING EARLY_PHASE1

Growth Factors in the Localized Gingival Recessions Treatment

NCT05188768

Localized Gingival Recession

COMPLETED NA

Platelet-Rich Fibrin Prepared With Titanium in the Treatment of Multiple Gingival Recessions

NCT05270941

Gingival Recession

COMPLETED NA

Effect of Dose-dependent Platelet Rich Fibrin(PRF)

NCT02882464

Gingival Recession

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

gingival recession (GR) is apical movement of the gingival margin beyond the cement-enamel junction. The use of free gingival grafts, sliding pedicle grafts, subepithelial connective tissue grafts, envelope or tunnelling techniques, the use of acellular dermal, connective tissue allografts, guided tissue regeneration, Platelet rich fibrin (PRF), and coronally advanced flap (CAF) are the surgical methods that have been developed to treat gingival recession. For treatments of intrabony defects, a synthetic nanocrystalline hydroxyapatite (NcHA) bone graft has been introduced. Osteoconductivity, bioresorbability, and close contact are benefits of NcHA material. Critical size defects showed quick healing when the NcHA was utilised as a bone graft alternative. NcHA binds to bone and increases osteoblast activity to promote bone regeneration. A promising bone replacement material, tricalcium phosphate (TCP) is known for its strong bioactivity and resorbable qualities. Tricalcium phosphate (TCP) is one of the most popular and effective artificial bone substitutes. It is osteoinductive as well as osteoconductive. These characteristics enable full bone defects regeneration together with its cell-mediated resorption. In this study, we compared between nanocrystalline hydroxyapatite and tricalcium phosphate carried on PRP membrane in treatment of Miller's class 1 gingival recession in human.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nanocrystalline hydroxyapatite

Nanocrystalline hydroxyapatite loaded in PRF+ coronally advanced flap

Group Type ACTIVE_COMPARATOR

coronally advanced flap

Intervention Type PROCEDURE

coronally advanced flap operation

Nanocrystalline hydroxyapatite loaded in PRF

Intervention Type OTHER

Nanocrystalline hydroxyapatite loaded in PRF

Nanocrystalline tricalcium phosphate (NcTCP)

Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF+ coronally advanced flap

Group Type ACTIVE_COMPARATOR

coronally advanced flap

Intervention Type PROCEDURE

coronally advanced flap operation

Nanocrystalline tricalcium phosphate loaded in PRF

Intervention Type OTHER

Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

coronally advanced flap

coronally advanced flap operation

Intervention Type PROCEDURE

Nanocrystalline hydroxyapatite loaded in PRF

Intervention Type OTHER

Nanocrystalline tricalcium phosphate loaded in PRF

Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with good systemic health and no contraindication for periodontal surgery.
* Patients who are able to maintain good oral hygiene.
* Gingival thickness for the site selected should be ≥1mm.
* The height of keratinized gingiva (HKG) for the site selected should be ≥1 mm (HKG is the distance between the most apical point of the gingival margin and the mucogingival junction).

Exclusion Criteria

* Active infectious diseases (hepatitis, tuberculosis, HIV, etc….).
* Medically compromised patients.
* Patients taking medications known to cause gingival enlargement.
* Pregnant patients and smokers.
* Previous mucogingival surgery at the defect.
* Restorations or caries in the area to be treated and non vital tooth.
* Teeth which are tilted or rotated.

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes